Genomas®, a biomedical company advancing DNA-Guided Medicine, has been awarded US Patent 7,747,392, entitled Physiogenomic Method for Predicting Clinical Outcomes of Treatment in Patients by the US Patent and Trademark Office.
Andreas Windemuth, Ph.D., Chief Technology Officer and co-inventor in the patent stated: "The PhyzioGenomics Technology has been successfully applied to several psychiatric and diabetes drugs and to brain imaging. The technology correlates genotypes and phenotypes in patient populations to discover clinically functional variability. The PhyzioGenomics Technology integrates a biomedical engineering systems approach with genome probes and nano-arrays."
Research on the PhyzioGenomics Technology has been published in the renowned journals Annals of Biomedical Engineering, Biomedical Engineering Handbook, Clinica Chimica Acta, Clinics in Laboratory Medicine, Molecular Psychiatry, Muscle & Nerve, Personalized Medicine, Pharmacogenomics, and Schizophrenia Research.
Gualberto Ruano, M.D., Ph.D., President of Genomas and co-inventor commented: "This fundamental patent covers also the configuration of our products and pipeline, the PhyzioTypeTM Systems. This is a landmark achievement for Genomas and allows us freedom to operate in our industry sector. In an otherwise crowded genomics landscape, and in the presence of an ever more stringent yardstick on novelty versus prior art, this patent significantly increases the value of our intellectual property portfolio and differentiates our proprietary PhyzioType products."
Filed in 2006, US Patent 7,747,392 comprises 23 methods claims and 384 polymorphic DNA sequences representative of 222 key cardiometabolic and neuroendocrine genes. Beyond this patent, the Intellectual Property portfolio of Genomas encompasses 5 patent applications, 2 trademarks, and a copyright on the company's clinical informatics system.
Can exercise undo sitting's health risks? New study suggests vigorous activity helps